Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Daly MB, Pal T, Buys SS et al (2022) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2022, NCCN clinical practice guidelines in oncology. March 9, https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503
2. Ettinger DS, Wood DE, Aismer DL et al (2022) NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer version 4.2022-September 2, NCCN.org
3. Benusiglio PR, Fallet V, Sanchis-Borja M et al (2021) Lung cancer is also a hereditary disease. Eur Respiratory Rev 30:210045. https://doi.org/10.1183/16000617.0045-2021
4. Kuzbari Z, Bandlamudi C, Loveday C et al (2023) Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol 34(3):215–227
5. de Shajani-Yi FB, Peterson JD et al (2018) Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma, and gliomas as identified by next-generation sequency. Neoplasia 20(3):256–262